EQS-Adhoc

Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Launches PKU GOLIKE(R) KRUNCH in Germany and Italy - Seite 2

The PKU GOLIKE(R) family of products are food for special medical purposes ("FSMP") consisting of a phenylalanine-free amino acid mix in granules. Engineered with the APR's Physiomimic Technology(TM), PKU GOLIKE(R) is the first prolonged-release amino acid product, characterized by a special coating that ensures a better physiological absorption of the amino acids, while also masking their unpleasant taste, odor and aftertaste.

"This newest launch by APR is a testament to the strength and adaptability of the Physiomimic Technology and is a key addition to our growing line of marketed products," stated Raghuram (Ram) Selvaraju, Chairman of the Board of Relief. "Moving forward, we plan to expand our existing commercial infrastructure and refine marketing activities to accelerate the future growth of this product line. It is also important to note that, since PKU GOLIKE(R) has been granted Orphan Drug Designation, we intend to assess the pursuit of PKU GOLIKE(R) as a prescription product for PKU in the U.S., where the majority of patients have no access to reimbursed medical foods."

ABOUT PHENYLKETONURIA OR PKU

PKU is a rare inherited disorder caused by a defect of the enzyme needed to break down phenylalanine, leading to a toxic buildup of phenylalanine when eating foods that contain protein or aspartame. Excessive levels of phenylalanine in the blood cause accumulation in the brain, which hampers proper brain development and results in neurophysiological dysfunction. Treatment of PKU is lifelong, requiring patients to follow a strict diet that severely limits phenylalanine (and, thus, protein) content. This necessitates supplementation of amino acid-based foods for special medical purposes (FSMP) to prevent protein deficiency and optimize metabolic control.

ABOUT RELIEF

Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief's lead drug candidate, RLF-100^TM (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy,